Brugada syndrome drugs to avoid: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Adding CME Category::Cardiology) |
|||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Brugada syndrome}} | {{Brugada syndrome}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
There are certain drugs that should be avoided in patients with Brugada syndrome. These drugs include [[ajmaline]], [[flecainide]], pilsicainide, [[procainamide]], and [[propafenone]]. These drugs are all sodium blocking [[antiarrhythmic]]s which are either in the IA class or IC class. | |||
==Drugs to Avoid== | |||
The following drugs should be avoided in patients with Brugada syndrome. <ref>www.brugadadrugs.org</ref><ref name="pmid19716089">{{cite journal |author=Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA |title=Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) |journal=[[Heart Rhythm : the Official Journal of the Heart Rhythm Society]] |volume=6 |issue=9 |pages=1335–41 |year=2009 |month=September |pmid=19716089 |pmc=2779019 |doi=10.1016/j.hrthm.2009.07.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S1547-5271(09)00739-5 |issn= |accessdate=2012-10-13}}</ref> | The following drugs should be avoided in patients with Brugada syndrome. <ref>www.brugadadrugs.org</ref><ref name="pmid19716089">{{cite journal |author=Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA |title=Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) |journal=[[Heart Rhythm : the Official Journal of the Heart Rhythm Society]] |volume=6 |issue=9 |pages=1335–41 |year=2009 |month=September |pmid=19716089 |pmc=2779019 |doi=10.1016/j.hrthm.2009.07.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S1547-5271(09)00739-5 |issn= |accessdate=2012-10-13}}</ref> | ||
<font size="- | <font size="-1"> | ||
{| cellspacing="2" cellpadding="3" border="0" | {| cellspacing="2" cellpadding="3" border="0" | ||
|- | |- | ||
| Line 59: | Line 63: | ||
Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence. | Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Electrophysiology]] | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category: | [[Category:Channelopathy]] | ||
[[Category: | [[Category:Genetic disorders]] | ||
Latest revision as of 05:44, 15 March 2016
|
Brugada syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Brugada syndrome drugs to avoid On the Web |
|
American Roentgen Ray Society Images of Brugada syndrome drugs to avoid |
|
Risk calculators and risk factors for Brugada syndrome drugs to avoid |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
There are certain drugs that should be avoided in patients with Brugada syndrome. These drugs include ajmaline, flecainide, pilsicainide, procainamide, and propafenone. These drugs are all sodium blocking antiarrhythmics which are either in the IA class or IC class.
Drugs to Avoid
The following drugs should be avoided in patients with Brugada syndrome. [1][2]
| Generic name | Brand name® | Class / Clinical use | References | Recommendation |
| Ajmaline | e.g. Gilurytmal® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Brugada 1997 Rolf 2003 Wolpert 2005 Bébarová 2005 |
Class I |
| Flecainide | e.g. Tambocor® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Krishnan 1998 Brugada 2000 Gasparini 2003 Meregalli 2006 Stokoe 2007 |
Class I |
| Pilsicainide | e.g. Sunrhythm® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Takenaka 1999 Fujiki 1999 Takagi 2002 Kimura 2004 |
Class I |
| Procainamide | e.g. Procan® Pronestyl® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Miyazaki 1996 Brugada 1997 Joshi 2007 Villemaire 1992 |
Class I |
| Propafenone | e.g. Rythmol® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Matana 2000 Akdemir 2002 Hasdemir 2006 Shan 2008 Stark 1996 |
Class IIa |
Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.
References
- ↑ www.brugadadrugs.org
- ↑ Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA (2009). "Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)". Heart Rhythm : the Official Journal of the Heart Rhythm Society. 6 (9): 1335–41. doi:10.1016/j.hrthm.2009.07.002. PMC 2779019. PMID 19716089. Retrieved 2012-10-13. Unknown parameter
|month=ignored (help)